CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 177 enrolled
Drug / intervention
ETC-1002 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01262638
NCT01262638Phase 2Completed
CompareCT.gov

A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.

Esperion Therapeutics, Inc.·interventional·Posted Dec 17, 2010·Updated Mar 17, 2021

In Brief

A Phase 2 clinical trial evaluating ETC-1002 and Placebo for Dyslipidemia. Completed, enrolled 177 participants across 11 sites.

Detailed Summary

This Phase 2 proof-of-concept study will assess the lipid regulating efficacy and safety of ETC-1002 in subjects with hypercholesterolemia and either normal or elevated triglycerides.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 17, 2010
Enrollment StartDec 1, 2010
Primary CompletionAug 23, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.5 years ago

Interventions

ETC-1002drug

ETC-1002 daily for 12 weeks

Placebodrug

Placebo daily for 12 weeks